Ex - US & Ex - UK Medical Media Only
Boehringer Ingelheim and Eli Lilly and Company today announced they will feature five oral and 12 poster presentations for linagliptin and the investigational compound empagliflozin* at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) which will take place in Barcelona, from 23 – 27 September. The presentations will add to the already existing body of data on safety and efficacy of these two compounds.
A total of eight clinical and pre-clinical abstracts for the investigational agent empagliflozin will be presented. Empagliflozin is a member of the sodium glucose cotransporter 2 (SGLT2) inhibitor class of drugs and is being investigated for the reduction of blood glucose levels in adults with Type 2 Diabetes (T2D).
Details of clinical empagliflozin presentations and published abstracts are as follows:1
Tuesday, 24 September, 12:30–13:30 CET, General Poster Session
Tuesday, 24 September, 13:45–14:45 CET, General Poster Session
Wednesday, 25 September, 12:30–13:30 CET, General Poster Session
Thursday, 26 September, 15:00 – 16:30 CET, Oral Presentation
* Empagliflozin is an investigational compound. Its safety and efficacy have not been established.
A total of nine clinical and pre-clinical abstracts for linagliptin will also be presented. Linagliptin is an inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), which breaks down the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) that are involved with regulating blood glucose.2
Details of all clinical presentations and published abstracts are as follows:1
Wednesday, 25 September, 10:45 – 12:15 CET, Oral Presentation
Wednesday, 25 September, 12:30 – 13:30 CET, General Poster Session
Wednesday, 25 September, 15:00 – 16:30 CET, Oral Presentation
Thursday, 26 September, 10:45 – 12:15 CET, Oral Presentation
Thursday, 26 September, 12:30 – 13:30 CET, General Poster Session
Thursday, 26 September, 13:45 – 14:45 CET, General Poster Session
Linagliptin, which is marketed as Trajenta® 5mg tablets in Europe, is a once-daily tablet used along with diet and exercise to improve glycaemic control in adults with Type 2 Diabetes. Linagliptin should not be used in patients with Type 1 Diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine). Linagliptin is the only approved DPP-4 inhibitor that does not require dose adjustments regardless of renal or hepatic function.
Please click on the link below for ‘Notes to Editors’ and ‘References’:
India Infoline News Service / 09:04, Jan 22, 2015
The outlook is a flat start. The market will look to scale to new peaks though not much effort is needed for the same. HUL saw a rally and short-covering may have pulled it up further. Speculation is on that its parent will raise stake through an open offer. After the cooling in oil prices, Cairn results will be in focus.